Comparative efficacy of targeted therapy, chemotherapy and their combination for advanced cholangiocarcinoma: a systematic review and network meta-analysis
All treatments significantly reduced the hazard ratio in OS and PFS when compared with the placebo.
This systematic review and network meta‑analysis evaluated overall survival (OS) and progression‑free survival (PFS) outcomes in advanced cholangiocarcinoma, comparing chemotherapy (CT), targeted therapy (TT), and combined targeted therapy + chemotherapy (TT+CT) to placebo. All three treatments significantly reduced the hazard ratio (HR) for OS and PFS when compared with placebo; TT+CT yielded the most favourable HR and mean difference (MD) values, and targeted therapy alone uniquely improved PFS.
Demonstrating that these therapeutic strategies can meaningfully prolong survival and delay disease progression informs clinical decision‑making and highlights the added value of combination regimens in advanced cholangiocarcinoma.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
- Scientists build cell line atlas of deadly cancers of the bile ducts and gallbladder
- Cholangiocarcinoma Workup: Laboratory Studies, Imaging Studies, Procedures
- New EASL Clinical Practice Guidelines on extrahepatic cholangiocarcinoma
- An open‑label study of pemigatinib in cholangiocarcinoma: final results from FIGHT‑202